32,061 Shares in Pacira BioSciences, Inc. (NASDAQ:PCRX) Bought by Segall Bryant & Hamill LLC

Segall Bryant & Hamill LLC purchased a new position in Pacira BioSciences, Inc. (NASDAQ:PCRX - Free Report) during the third quarter, according to its most recent Form 13F filing with the SEC. The fund purchased 32,061 shares of the company's stock, valued at approximately $483,000. Segall Bryant & Hamill LLC owned approximately 0.07% of Pacira BioSciences as of its most recent SEC filing.

Other hedge funds have also recently made changes to their positions in the company. Vanguard Group Inc. raised its stake in Pacira BioSciences by 0.3% during the first quarter. Vanguard Group Inc. now owns 5,113,384 shares of the company's stock valued at $149,413,000 after buying an additional 14,960 shares during the last quarter. Pacer Advisors Inc. raised its position in shares of Pacira BioSciences by 37.5% in the 2nd quarter. Pacer Advisors Inc. now owns 2,162,787 shares of the company's stock worth $61,877,000 after purchasing an additional 590,082 shares during the last quarter. Renaissance Technologies LLC boosted its stake in Pacira BioSciences by 9.8% in the 2nd quarter. Renaissance Technologies LLC now owns 2,066,197 shares of the company's stock worth $59,114,000 after purchasing an additional 184,000 shares in the last quarter. Dimensional Fund Advisors LP boosted its stake in Pacira BioSciences by 12.2% in the 2nd quarter. Dimensional Fund Advisors LP now owns 1,828,065 shares of the company's stock worth $52,300,000 after purchasing an additional 198,936 shares in the last quarter. Finally, Doma Perpetual Capital Management LLC grew its position in Pacira BioSciences by 71.8% during the 2nd quarter. Doma Perpetual Capital Management LLC now owns 1,000,761 shares of the company's stock valued at $28,632,000 after purchasing an additional 418,321 shares during the last quarter. 99.73% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several research analysts have recently issued reports on PCRX shares. Raymond James downgraded shares of Pacira BioSciences from an "outperform" rating to a "market perform" rating in a research note on Monday, August 12th. Jefferies Financial Group increased their target price on Pacira BioSciences from $15.00 to $18.00 and gave the company a "buy" rating in a research note on Tuesday, September 24th. Piper Sandler downgraded Pacira BioSciences from an "overweight" rating to a "neutral" rating and lowered their price target for the company from $42.00 to $11.00 in a report on Monday, August 12th. Truist Financial cut Pacira BioSciences from a "buy" rating to a "sell" rating and dropped their price objective for the company from $30.00 to $8.00 in a research report on Tuesday, August 13th. Finally, Barclays decreased their target price on Pacira BioSciences from $25.00 to $17.00 and set an "equal weight" rating for the company in a research report on Tuesday, November 12th. Two research analysts have rated the stock with a sell rating, four have given a hold rating and five have issued a buy rating to the company. According to MarketBeat.com, the company currently has an average rating of "Hold" and an average price target of $23.50.

Pacira BioSciences Stock Performance

Shares of NASDAQ:PCRX traded down $0.13 during trading on Monday, hitting $17.42. The company's stock had a trading volume of 532,332 shares, compared to its average volume of 849,622. The company has a debt-to-equity ratio of 0.51, a current ratio of 2.25 and a quick ratio of 1.89. The firm has a market cap of $804.28 million, a price-to-earnings ratio of -8.67 and a beta of 0.82. The company has a 50-day moving average of $16.21 and a 200-day moving average of $20.23. Pacira BioSciences, Inc. has a 12 month low of $11.16 and a 12 month high of $35.95.

About Pacira BioSciences

Pacira BioSciences, Inc engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature to targeted nerves.